Sun Pharma dips 5% on confirmation of USFDA inspection of Halol facility
The stock was down 5% after the company confirms that Halol facility has undergone an inspection by USFDA
 "Sun Pharma dips 5% on confirmation of USFDA inspection of Halol facility")
Sun Pharmaceutical Industries has dipped 5% to Rs 669 on the National Stock Exchange (NSE) in noon deals, after the drug maker confirmed that its Halol facility had undergone an inspection by US Food and Drug Administration (FDA) recently.
“The inspection was completed on 01-December-2016. A Form-483 observation letter was issued by the US FDA post the inspection,” Sun Pharma said on clarification of news report that "USFDA informs that Halol issued 14 page Form 483 post inspection"
Sun Pharma said it is currently in the process of responding to the said letter to the US FDA within the stipulated timeline of 15 days. CLICK HERE FOR THE RELEASE TO THE BSE
Till 01:35 pm; a combined 8.36 million shares changed hands on the counter on the NSE and BSE.
“The inspection was completed on 01-December-2016. A Form-483 observation letter was issued by the US FDA post the inspection,” Sun Pharma said on clarification of news report that "USFDA informs that Halol issued 14 page Form 483 post inspection"
Sun Pharma said it is currently in the process of responding to the said letter to the US FDA within the stipulated timeline of 15 days. CLICK HERE FOR THE RELEASE TO THE BSE
Till 01:35 pm; a combined 8.36 million shares changed hands on the counter on the NSE and BSE.